Navigation Links
Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
Date:10/15/2008

/p>

Significant Q3 2008 transactions and events

The commercial launch of ORALAIR(R) Grasses for adults took place in Germany at the end of July. The product was well received by allergy professionals. However, ORALAIR(R) Grasses' sales over the quarter were not significant since the launch occurred after the pollen season.

The marketing licence of ORALAIR(R) Grasses in its paediatric indication, which should be delivered by the German agency before the end of the year, will mark the start of the European mutual recognition registration procedure of the product.

The roll-out of the ORALAIR(R) Mites phase II/III pivotal study, initiated at the end of 2007, is continuing satisfactorily.

Lastly, Stallergenes expanded its product range following the exclusive agreement announced on 7 October for the promotion and distribution in Europe of an adrenalin auto-injector, jointly developed and manufactured by Catalent and The Medical House PLC.

Outlook for the current financial year

Due to the strong sales recorded over the quarter, the Company is in a position, for the second time this year, to review its 2008 full-year sales guidance upwards. Sales growth in the region of 14% is now expected.

As a result, at the same time as implementing a significant research and development expenditure programme, the Group's guidance is for full-year net profit slightly higher than in the previous financial year, as well as a further improved financial position, which will enhance its development resources.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitisation therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitisation treatment, Stallergenes devotes 20% in raw data of its sales to Research and Development and is actively involved in the development of a new t
'/>"/>

SOURCE Stallergenes
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
2. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
3. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
4. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
5. Newly Integrated Software Suite From ZS Associates Offers Comprehensive Set of Sales Performance Management Software Solutions
6. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
7. Guillermo Moreno Named Aurillions Vice President of Sales and Marketing
8. Genstruct Names Louis Latino VP of Sales
9. BioElectronics Corp Aggressively Expands Sales into Middle East
10. Campbell Alliance Sales Practice to Present at CBIs Leadership Summit on Evolving the Pharma Sales Model
11. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015 Tauriga Sciences, Inc. (OTCQB:  TAUG) or ... today announced that its stockholders approved an increase in ... the Company from 1,000,000,000 to 2,500,000,000 at its Special ... the Law Offices of Nixon Peabody LLP in Midtown ... were 480,655,929 shares of common stock represented either by ...
(Date:7/28/2015)... NEWPORT BEACH, Calif. , July 28, 2015 ... company, announced that it has hit a milestone ... Putty. Signafuse was FDA 510(k) cleared in early ... standalone use in posterolateral spine fusion procedures.  This ... graft products, as less than 6% of new ...
(Date:7/28/2015)... RESEARCH TRIANGLE PARK, N.C., July 28, 2015  United ... its financial results for the second quarter ended ... nearly 300% as compared to the second quarter ... said Roger Jeffs, Ph.D., United Therapeutics, President and ... was due to an increase in the number ...
(Date:7/27/2015)... OAKS, Calif. , July 27, 2015  Amgen ... report its second quarter financial results on Thursday, July ... markets. The announcement will be followed by a conference ... Participating in the call from Amgen will be ... and other members of Amgen,s senior management team. ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Revolutionary Bone Graft Exceeds Expectations 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Amgen Announces Webcast of 2015 Second Quarter Financial Results 2
... , Interleukin 13 is a recently described cytokine ... is responsible for both positive and negative responses , ... to modulate macrophage functions as well as play ... and differentiation of hematopoietic stem cells. In addition, , ...
... and their metabolites are, important intracellular signals ... of hormones and growth, factors.The discovery of ... the 3 position of, the inositol ring ... and potential intracellular signals., Phosphoinositide 3-kinase has been ...
... S and CHT , Ceramic ... Henry Lai, PhD, and Samuel G Franklin, PhD, Bio-Rad Laboratories, Inc., , ... , Introduction , ... , using the conventional process composed of a protein ...
Cached Biology Technology:Purification of rIL-13 Using an UNO Q1 Column 2Purification of Phosphoinositide 3-Kinase With UNO Columns 2Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 2Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 3Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 4
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. ... molecular diagnostics, today announced the launch of a ... Company,s Precision Cancer Monitoring℠ (PCM) technology for predicting ... one or a combination of the novel immunotherapy ... (nivolumab), a PD-1 inhibitor. The 50-patient study will ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... alliance of conservation groups battling global extinctions has saved ... species. , American Bird Conservancy (ABC), Conservation International (CI), ... the 1,600-acre site on the northwest slope of the ... coast of Colombia, before its development for vacation homes. ...
... The University of Manchester and the Manchester Metropolitan University ... ancient spiders trapped in amber more than 30 millions ... the Baltic (Poland) and the Dominican (Caribbean) regions has ... back to the Cenozoic period. , It is the ...
... the U.S. Geological Survey released a report describing the ... 1992-2001. The report concludes that pesticides are typically present ... agricultural areas of the Nation, but are less common ... pesticides are seldom at concentrations likely to affect humans. ...
Cached Biology News:Crucial site for endangered frogs and birds saved 2Amber reveals ecology of 30 million year old spiders 2Pesticides in the nation's streams and ground water 2Pesticides in the nation's streams and ground water 3Pesticides in the nation's streams and ground water 4